Biopharma’s buyout year ends with a bang
A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.
CSL pays $11.7bn for new blood
The biggest biopharma deal of the year is also the biggest the Australian group has ever done.
Pfizer starts to put its vaccine cash to use
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
AHA 2021 – Bristol touts its Eliquis follow-on
Phase 2 data with milvexian look good, but Eliquis will be a hard act to follow.
Jaks capped in arthritis – but the FDA might not be finished
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
Biotech’s important upcoming data
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
